Author Information
Dr.Rabia has 25 Published Articles

United States of America,
TX,
Houston,
Houston, TX 77055 USA,



AR-42 FUNCTIONS AGAINST NEUROFIBROMATOSIS TYPE 2

Posted On : Jan-20-2012 | seen (740) times | Article Word Count : 578 |

Histone deacetylases is the name given to the enzymes responsible of catalyzing the removal of acetyl groups attached to lysine residues. These histone deacetylases have ability of increases the condensation of chromatin material and represses the transcription process. Including this these histone deacetylases causes epigenetic silencing.
INTRODUCTION

Histone deacetylases is the name given to the enzymes responsible of catalyzing the removal of acetyl groups attached to lysine residues. These histone deacetylases have ability of increases the condensation of chromatin material and represses the transcription process. Including this these histone deacetylases causes epigenetic silencing. HDACs, separately from histone proteins are capable of affecting the transcription factors, activity of chaperones different signaling components and cytoskeletal proteins. So the inhibitor which is specially designed in lab to function against HDACs must be showing diverse properties inside the cells. One important example of such inhibitor is AR-42 which has the real potency to act against cancers under in vivo environment.

An important property of HDAC inhibitors is their very specific activity. An HDAC 6 inhibitor named Vorinostat (SAHA) is a major example of such inhibitors. AR-42 was used against malignant B-cells under in vivo and in vitro conditions. AR-42 is a hydroxamic acid derivative having bound phenyl butyrate and is very effective against various types of tumors in solid form. It causes the reduction in surviving, Bcl-xL and p-Akt levels. As compared to Vorinostat AR-42 was found more effective in its activity on these proteins. Its main rule of action is to trigger apoptosis and check the growth process of tumor cells. Hence found to be an efficient HDAC inhibitor in B-cell malignancies.

Chronic Lymphocytic Leukemia commonly known as CLL is actually the adenopathy in lymphoid tissues and the breakdown or collapse in bone marrow. Histone deacetylase inhibitors for example entinostat and valproate are responsible of enhancing cytotoxic level of these cancerous cells. These inhibitors have a direct action on caspases hence stimulate apoptosis. On the basis of these findings AR-42 was studied and tested against Chronic Lymphocytic Leukemia and was found to be very valuable apoptosis inhibitor.

T-cells malignancies in adult human beings is caused by I specific kind of virus known as HTLV-1. Such lymphoma is also called as adult T-cell lymphoma or ATL. This specific cancer type is mostly found to have a resistance against various types of chemical anti-cancer agents. AR-42 causes the induction of apoptosis in these cells and check the further growth and proliferation. Type 2 Neurofibromatosis is a result of an autosomal-dominant gene mutation. Due to these genes various schwannomas and meningiomas are formed in vestibular parts. AR-42 when used in 500mM concentration causes inhibition of schwannoma cells formation. While at concentration 1.5 µM it causes inhibition of meningioma cells growth. Its use causes the cell cycle arrest at phase Gap 2 stimulating apoptosis. Under in vivo environment p-Akt levels are also checked by the use of AR-42. Hence these results show the efficacy of this compound to induce the cancer cell death by apoptosis.

Kit mutations were observed when AR-42 which is a HDAC inhibitor was applied to canine cells. Three activities were efficiently shown i.e inhibition of growth process, arrest of cell cycle and stimulation of apoptosis. The basic mechanism is actually the activation of caspase 7 or caspase 3, over acetylation of H3 and H4 histone proteins and up-regulation of levels of α- tubulin and p21.

CONCLUSION

In short, as compare to vorinostat, AR-42 is more potential HDAC inhibitor and found to more efficient and valuable in case of various kinds of cancers especially leukemia. This inhibitor is undergoing clinical evaluation and is very promising in future for the blood cancers such as chronic lymphocytic leukemia.

Article Source : http://www.articleseen.com/Article_AR-42 FUNCTIONS AGAINST NEUROFIBROMATOSIS TYPE 2 _136644.aspx

Author Resource :
We pays great attention to the purity, stability and activity of the products like xl880, PF-2341066, Bortezomib & more.

Keywords : PF-2341066, Bortezomib,

Category : Health and Fitness : Medicine

Bookmark and Share Print this Article Send to Friend